TheraRadar
Clinical-Stage Companies / Laboratoires Thea

Laboratoires Thea

Pre-Approval PRO BETA
33
Total Trials
13
Phase 3
14
Phase 2
6
Recruiting
342
Score

Pipeline by Phase

Phase 3
13
Phase 2
14
Phase 1
5

Therapeutic Focus

Glaucoma Ocular Hypertension Retinal Disease Eye Diseases, Hereditary Eye Disorders Congenital

Clinical Trials (33)

NCT06891443 Phase 3 RECRUITING

Study to Evaluate Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Type 10 (HYPERION)

Started: 6/4/2025

NCT05397600 Phase 3 COMPLETED

Efficacy and Safety Assessment of T4032 (Unpreserved Bimatoprost 0.01%) Versus Lumigan® 0.01% in Ocular Hypertensive or Glaucomatous Patients

Started: 6/22/2022

NCT03825380 Phase 3 COMPLETED

Efficacy and Safety Assessment of T4032 Versus Lumigan® in Ocular Hypertensive or Glaucomatous Patients

Started: 11/23/2018

NCT04898387 Phase 3 COMPLETED

Efficacy and Safety Assessment of T4030 Eye Drops Versus Ganfort® UD in Ocular Hypertensive or Glaucomatous Patients.

Started: 3/26/2021

NCT01794312 Phase 3 COMPLETED

Efficacy and Safety Assessment of T4020 Versus Vehicule in Patients With Chronic Neurotrophic Keratitis or Corneal Ulcer

Started: 2/1/2013

NCT02023268 Phase 3 COMPLETED

Efficacy and Safety of T2762 and Vismed® in Dry Eye Syndrome

Started: 12/1/2013

NCT02278614 Phase 3 COMPLETED

Efficacy and Safety Assessment of T2347 Versus Xalacom® in Ocular Hypertensive or Glaucomatous Patients

Started: 12/1/2014

NCT01568593 Phase 3 COMPLETED

Comparison of the Efficacy and Safety of T2750 and Vismed® in the Treatment of Moderate to Severe Dry Eye Syndrome

Started: 3/1/2012

NCT01156012 Phase 3 COMPLETED

Efficacy and Safety Assessment of T2345 in Ocular Hypertensive or Glaucomatous Patients

Started: 9/1/2009

NCT02101359 Phase 3 COMPLETED

Efficacy and Safety Assessment of Intracameral Injection of T2380 in Cataract Surgery

Started: 6/1/2011

NCT01155999 Phase 3 COMPLETED

Clinical Efficacy and Safety of T1225 Versus Tobramycin 0.3 % Eye Drops in the Treatment of Purulent Bacterial Conjunctivitis of Children.

Started: 12/1/2008

NCT07169695 Phase 2 RECRUITING

A Study to Compare the Effectiveness and Safety of T1695 Versus Ciclosporin in Participants With Moderate to Severe Vernal Keratoconjunctivitis

Started: 3/24/2026

NCT07522242 Phase 2 RECRUITING

Safety and Efficacy of T10430 Eye Drops in Controlling Paediatric Myopia Progression

Started: 1/21/2026

NCT06627179 Phase 2 RECRUITING

Study to Evaluate Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene

Started: 12/11/2024

NCT06394973 Phase 2 COMPLETED

Efficacy and Safety Assessment of T4090 Ophthalmic Solution Versus Rhopressa® Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension

Started: 8/5/2024

NCT05176717 Phase 2 TERMINATED

Study to Evaluate the Efficacy Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene With Early to Moderate Vision Loss (Celeste)

Started: 12/15/2021

NCT05085964 Phase 2 TERMINATED

An Open-Label Extension Study to Evaluate Safety & Tolerability of QR-421a in Subjects With Retinitis Pigmentosa

Started: 9/16/2021

NCT05158296 Phase 2 TERMINATED

Study to Evaluate the Efficacy Safety and Tolerability of Ultevursen in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene (Sirius)

Started: 12/8/2021

NCT01494753 Phase 2 COMPLETED

Pharmacokinetics, Efficacy and Safety Assessment of T2345 Compared With Active Comparator in Newly Diagnosed Patients With Open-angle Glaucoma or Ocular Hypertension

Started: 6/1/2008

NCT01089608 Phase 2 COMPLETED

Efficacy and Safety Assessment of Azyter® Eye Drops (T1225) in Patients With Blepharitis

Started: 3/1/2010

NCT01344083 Phase 2 COMPLETED

Comparison of the Efficacy and Tolerability of T1210 and Olopatadine Hydrochloride 0.1% in the Treatment of Seasonal Allergic Conjunctivitis

Started: 4/1/2011

NCT01156025 Phase 2 COMPLETED

Efficacy and Safety of GV 550 in Acute Adenovirus Keratoconjunctivitis

Started: 3/1/2009

NCT03140969 Phase 1 COMPLETED

Study to Evaluate QR-110 in Leber's Congenital Amaurosis (LCA) Due to the c.2991+1655A>G Mutation (p.Cys998X) in the CEP290 Gene

Started: 10/16/2017

NCT03913130 Phase 1 TERMINATED

Extension Study to Study PQ-110-001 (NCT03140969)

Started: 5/13/2019

NCT05389267 Phase 1 ACTIVE NOT RECRUITING

Safety Assessment of T4090 Eye Drops in Ocular Hypertensive or Glaucomatous Patients.

Started: 7/5/2022

NCT05729594 Phase 1 COMPLETED

Systemic Pharmacokinetic Study of T4032 (Unpreserved Bimatoprost 0.01%) Eye Gel Versus Lumigan® 0.01% Eye Drops in 40 Healthy Volunteers

Started: 2/27/2023

NCT01190397 Phase 1 COMPLETED

Warming Efficiency of Warm Compresses Versus BLEPHASTEAM® in Eyelid Therapy

Started: 9/1/2010

NCT06903741 Phase 4 RECRUITING

New Preservative-free Combination of Trehalose, Sodium Hyaluronate and N-acetyl-aspartyl-glutamate (NAAGA) in Dry Eye

Started: 10/21/2025

NCT02017327 Phase 4 COMPLETED

Safety and Efficacy Assessment of Monoprost® in Comparison With Lumigan® 0.01 % and Lumigan® 0.03% Unit Dose

Started: 12/1/2013

NCT01155219 Phase 4 COMPLETED

Safety, Efficacy Assessment of Geltim LP® 1 mg/g in Ocular Hypertensive or Glaucomatous Patients.

Started: 7/1/2008

NCT01189474 Phase 4 COMPLETED

Evaluation of Satisfaction Regarding Patient's Management of Ocular Surface Diseases

Started: 6/1/2010

NCT01203540 Phase 4 COMPLETED

Evaluation of the Effect and Tolerance of Preservative Free NAAGA on the Inflammatory Component and Symptoms of Dry Eye Syndrome in Allergic Conjunctivitis Patients

Started: 10/1/2010

NCT01091311 Phase 4 COMPLETED

Evaluation of Satisfaction Regarding Patient's Management of Ocular Surface Diseases

Started: 5/1/2010

Drug Candidates

T1695 Ciclosporin T10430 lower dose T10430 middle dose T10430 higher dose Vehicle Intravitreal Injection of Ultevursen sepofarsen T4090 0.2% T4090 0.3%
Activity Status: Active
Last Trial Started: 3/24/2026
Last Trial Ended: 11/21/2024
Trials (12 months): 4
Completed Trials: 23
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.